NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight

E. Dombi, J. Solomon, A. J. Gillespie, E. Fox, F. M. Balis, N. Patronas, B. R. Korf, Dusica Babovic-Vuksanovic, R. J. Packer, J. Belasco, S. Goldman, R. Jakacki, M. Kieran, S. M. Steinberg, B. C. Widemann

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

OBJECTIVE: To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis type 1 and inoperable, symptomatic, or progressive PNs, using a sensitive, automated method of volumetric MRI analysis. METHODS: We included patients 25 years of age and younger with PNs entered in a natural history study or in treatment trials who had volumetric MRI over ≥16 months. RESULTS: We studied 49 patients (median age 8.3 years) with 61 PNs and a median evaluation period of 34 months (range 18 to 70). The PN growth rates varied among patients, but were constant within patients. Thirty-four patients (69%) experienced ≥20% increase in PN volume during the observation period. PN volume increased more rapidly than body weight over time (p = 0.026). Younger patients had the most rapid PN growth rate. CONCLUSIONS: Volume increase of plexiform neurofibromas is a realistic and meaningful trial endpoint. In most patients plexiform neurofibroma growth rate exceeded body growth rate. The youngest patients had the fastest plexiform neurofibroma growth rate, and clinical drug development should be directed toward this population. Age stratification for clinical trials for plexiform neurofibromas should be considered.

Original languageEnglish (US)
Pages (from-to)643-647
Number of pages5
JournalNeurology
Volume68
Issue number9
DOIs
StatePublished - Feb 1 2007

Fingerprint

Plexiform Neurofibroma
Body Weight
Growth
Neurofibromatosis 1
Natural History
Young Adult
Observation
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Dombi, E., Solomon, J., Gillespie, A. J., Fox, E., Balis, F. M., Patronas, N., ... Widemann, B. C. (2007). NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology, 68(9), 643-647. https://doi.org/10.1212/01.wnl.0000250332.89420.e6

NF1 plexiform neurofibroma growth rate by volumetric MRI : Relationship to age and body weight. / Dombi, E.; Solomon, J.; Gillespie, A. J.; Fox, E.; Balis, F. M.; Patronas, N.; Korf, B. R.; Babovic-Vuksanovic, Dusica; Packer, R. J.; Belasco, J.; Goldman, S.; Jakacki, R.; Kieran, M.; Steinberg, S. M.; Widemann, B. C.

In: Neurology, Vol. 68, No. 9, 01.02.2007, p. 643-647.

Research output: Contribution to journalArticle

Dombi, E, Solomon, J, Gillespie, AJ, Fox, E, Balis, FM, Patronas, N, Korf, BR, Babovic-Vuksanovic, D, Packer, RJ, Belasco, J, Goldman, S, Jakacki, R, Kieran, M, Steinberg, SM & Widemann, BC 2007, 'NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight', Neurology, vol. 68, no. 9, pp. 643-647. https://doi.org/10.1212/01.wnl.0000250332.89420.e6
Dombi, E. ; Solomon, J. ; Gillespie, A. J. ; Fox, E. ; Balis, F. M. ; Patronas, N. ; Korf, B. R. ; Babovic-Vuksanovic, Dusica ; Packer, R. J. ; Belasco, J. ; Goldman, S. ; Jakacki, R. ; Kieran, M. ; Steinberg, S. M. ; Widemann, B. C. / NF1 plexiform neurofibroma growth rate by volumetric MRI : Relationship to age and body weight. In: Neurology. 2007 ; Vol. 68, No. 9. pp. 643-647.
@article{2115e3633b5141eba33bb0cc432584f6,
title = "NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight",
abstract = "OBJECTIVE: To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis type 1 and inoperable, symptomatic, or progressive PNs, using a sensitive, automated method of volumetric MRI analysis. METHODS: We included patients 25 years of age and younger with PNs entered in a natural history study or in treatment trials who had volumetric MRI over ≥16 months. RESULTS: We studied 49 patients (median age 8.3 years) with 61 PNs and a median evaluation period of 34 months (range 18 to 70). The PN growth rates varied among patients, but were constant within patients. Thirty-four patients (69{\%}) experienced ≥20{\%} increase in PN volume during the observation period. PN volume increased more rapidly than body weight over time (p = 0.026). Younger patients had the most rapid PN growth rate. CONCLUSIONS: Volume increase of plexiform neurofibromas is a realistic and meaningful trial endpoint. In most patients plexiform neurofibroma growth rate exceeded body growth rate. The youngest patients had the fastest plexiform neurofibroma growth rate, and clinical drug development should be directed toward this population. Age stratification for clinical trials for plexiform neurofibromas should be considered.",
author = "E. Dombi and J. Solomon and Gillespie, {A. J.} and E. Fox and Balis, {F. M.} and N. Patronas and Korf, {B. R.} and Dusica Babovic-Vuksanovic and Packer, {R. J.} and J. Belasco and S. Goldman and R. Jakacki and M. Kieran and Steinberg, {S. M.} and Widemann, {B. C.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1212/01.wnl.0000250332.89420.e6",
language = "English (US)",
volume = "68",
pages = "643--647",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - NF1 plexiform neurofibroma growth rate by volumetric MRI

T2 - Relationship to age and body weight

AU - Dombi, E.

AU - Solomon, J.

AU - Gillespie, A. J.

AU - Fox, E.

AU - Balis, F. M.

AU - Patronas, N.

AU - Korf, B. R.

AU - Babovic-Vuksanovic, Dusica

AU - Packer, R. J.

AU - Belasco, J.

AU - Goldman, S.

AU - Jakacki, R.

AU - Kieran, M.

AU - Steinberg, S. M.

AU - Widemann, B. C.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - OBJECTIVE: To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis type 1 and inoperable, symptomatic, or progressive PNs, using a sensitive, automated method of volumetric MRI analysis. METHODS: We included patients 25 years of age and younger with PNs entered in a natural history study or in treatment trials who had volumetric MRI over ≥16 months. RESULTS: We studied 49 patients (median age 8.3 years) with 61 PNs and a median evaluation period of 34 months (range 18 to 70). The PN growth rates varied among patients, but were constant within patients. Thirty-four patients (69%) experienced ≥20% increase in PN volume during the observation period. PN volume increased more rapidly than body weight over time (p = 0.026). Younger patients had the most rapid PN growth rate. CONCLUSIONS: Volume increase of plexiform neurofibromas is a realistic and meaningful trial endpoint. In most patients plexiform neurofibroma growth rate exceeded body growth rate. The youngest patients had the fastest plexiform neurofibroma growth rate, and clinical drug development should be directed toward this population. Age stratification for clinical trials for plexiform neurofibromas should be considered.

AB - OBJECTIVE: To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis type 1 and inoperable, symptomatic, or progressive PNs, using a sensitive, automated method of volumetric MRI analysis. METHODS: We included patients 25 years of age and younger with PNs entered in a natural history study or in treatment trials who had volumetric MRI over ≥16 months. RESULTS: We studied 49 patients (median age 8.3 years) with 61 PNs and a median evaluation period of 34 months (range 18 to 70). The PN growth rates varied among patients, but were constant within patients. Thirty-four patients (69%) experienced ≥20% increase in PN volume during the observation period. PN volume increased more rapidly than body weight over time (p = 0.026). Younger patients had the most rapid PN growth rate. CONCLUSIONS: Volume increase of plexiform neurofibromas is a realistic and meaningful trial endpoint. In most patients plexiform neurofibroma growth rate exceeded body growth rate. The youngest patients had the fastest plexiform neurofibroma growth rate, and clinical drug development should be directed toward this population. Age stratification for clinical trials for plexiform neurofibromas should be considered.

UR - http://www.scopus.com/inward/record.url?scp=33947530697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947530697&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000250332.89420.e6

DO - 10.1212/01.wnl.0000250332.89420.e6

M3 - Article

C2 - 17215493

AN - SCOPUS:33947530697

VL - 68

SP - 643

EP - 647

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -